Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rosa, Roberta, Damiano, Vincenzo, Formisano, Luigi, Nappi, Lucia, Marciano, Roberta, Veneziani, Bianca Maria, De Placido, Sabino, Bianco, Roberto
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Author's View
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782521/
https://ncbi.nlm.nih.gov/pubmed/24083076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.25123
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars